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Management of Paediatric Ulcerative Colitis, Part 2:
Acute Severe Colitis—An Evidence-based Consensus
Guideline From the European Crohn’s and Colitis
Organization and the European Society of Paediatric
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ABSTRACT
Background and aim: Acute severe colitis (ASC) is one of the few
emergencies in pediatric gastroenterology. Tight monitoring and timely
medical and surgical interventions may improve outcomes and minimize
morbidity and mortality. We aimed to standardize daily treatment of ASC in
children through detailed recommendations and practice points which are
based on a systematic review of the literature and consensus of experts.
Methods: These guidelines are a joint effort of the European Crohn’s and
Colitis Organization (ECCO) and the European Society of Paediatric
Gastroenterology, Hepatology and Nutrition (ESPGHAN). Fifteen
predefined questions were addressed by working subgroups. An iterative
consensus process, including 2 face-to-face meetings, was followed by
voting of the national representatives of ECCO and all members of the
Paediatric Inflammatory Bowel Disease (IBD) Porto group of ESPGHAN
(43 voting experts).
Results: A total of 24 recommendations and 43 practice points were
endorsed with a consensus rate of at least 91% regarding diagnosis,
monitoring, and management of ASC in children. A summary flowchart
is presented based on daily scoring of the Paediatric Ulcerative Colitis
Activity Index. Several topics have been altered since the previous 2011
guidelines and from those published in adults.
Discussion: These guidelines standardize the management of ASC in children
in an attempt to optimize outcomes of this intensive clinical scenario.
Key Words: acute severe colitis, antibiotics, anti-coagulants, anti-TNF,
colectomy, mesalamine, Pediatric Ulcerative Colitis Activity Index,
prediction, steroids, ulcerative colitis
(JPGN 2018;67: 292–310)
What Is Known
 The previously published European Society of Paedi-
atric Gastroenterology, Hepatology and Nutrition
and European Crohn’s and Colitis Organization
guidelines on acute severe colitis were published in
2011 and are updated herein.
What Is New
 In addition to providing an update of new literature,
several major topics have changed from the previous
guidelines. A Paediatric Ulcerative Colitis Activity
Index-based algorithm dictates a day-by-day thera-
peutic and monitoring management; the use of
thrombotic prophylaxis has been revisited based
on predicting variables; sequential therapy has been
newly presented; recommendations for therapeutic
drug monitoring have been provided; and other
sections updated.
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INTRODUCTION
A cute severe ulcerative colitis (ASC), a medical emergency inchildren, is defined by a Paediatric Ulcerative Colitis Activity
Index (PUCAI) score of at least 65 points (1–3) (Table 1). Pediatric-
onset ulcerative colitis (UC) is often more extensive than in adults and
more dynamic in progression (4,5). Since disease severity has been
consistently associated with disease extent, children are especially
susceptible to refractory severe attacks. The Hungarian Paediatric
Inflammatory Bowel Disease Registry (HUPIR), reported that 11%
children had severe disease at some stage during the disease course of
UC (6). In an Italian cohort of 109 children, 9% presented with ASC and
23% had at least 1 episode by the end of the follow-up of 48 months (7).
Comparable rates were found in a multicenter pediatric UC inception
cohort, in which 15% of children developed ASC within 3 months of
diagnosis (8). In an older population-based retrospective cohort, 28% of
children required hospitalization within the first 3 years of disease (9).
The difference between the older and newer cohorts possibly reflects the
advent of biologics which allow outpatient treatment of some children
with UC.
With few exceptions, children with ASC should be admitted to
hospital for immediate evaluation and intensive medical treatment
with intravenous corticosteroids (IVCS). A PUCAI 65 is associated
with a more refractory disease course in pediatric UC, both at disease
onset and thereafter (8–10). In a systematic review, the pooled
steroid-refractory rate in ASC across all pediatric studies was 34%
(11), slightly higher than the pooled 29% rate found in adult studies
(12). In 2 pediatric inception cohorts, the occurrence of ASC was
associated with an increased risk of colectomy (7,8). The advent of
calcineurin inhibitors and infliximab has reduced the short-term
colectomy rate from between 40% to 70% (9,11–13) to approxi-
mately 10% to 20% in children (10,14,15) and the 1-year colectomy
rate from 60% (9,16) to between 18% to 22% (10,14,16). Among
those who fail IVCS treatment, roughly 50% to 60% of responders to
salvage medical therapy will require colectomy within 1 to 2 years
(10,14). To add to the complexity, enteric infections, and adverse
events to medications (primarily mesalamine and thiopurines) can
mimic ASC. Consequently, a child who ever developed an episode of
ASC is at a particular risk for a more refractory disease course and
colectomy and is labeled by the Paris classification as S1 (17).
Mortality in ASC has decreased in adults from over 70% in
1933 to 20% to 25% in the 1950s when the importance of timely
urgent colectomy was first recognized (18,19). Later, the mortality
rate was further reduced to 7% with the introduction of IVCS as the
mainstay of treatment, and eventually to<1% nowadays (12,20–22).
Address correspondence and reprint requests to Dan Turner, Shaare
Zedek Medical Center, Jerusalem, Israel
(e-mail: turnerd@szmc.org.il).
Supplemental digital content is available for this article. Direct URL
citations appear in the printed text, and links to the digital files are
provided in the HTML text of this article on the journal’s Web site
(www.jpgn.org).
ESPGHAN is not responsible for the practices of physicians and provides
guidelines and position papers as indicators of best practice only.
Diagnosis and treatment is at the discretion of physicians.
The study was supported by ECCO and ESPGHAN.
D.T. for last 3 years received consultation fee, research grant, royalties, or
honorarium from Janssen, Pfizer, Hospital for Sick Children (UC
activity index royalties from industry trials), Ferring, AstraZeneca,
Abbvie, Takeda, Ferring, Boehringer Ingelheim, Biogen, Atlantic
Health, Shire, and Celgene; J.M.d.C., last 3 years received consultation
fee, research grant, travel grant, or honorarium from Abbvie, Abbot,
Nestle, MSD, Otsuka, Faes, Nutricia, and Fresenius; J.B. received
honoraria, speaker’s fees and/or congress fees from AbbVie, MSD,
Nestle, Nutricia, and Biocodex. G.V., received consultation fee from
Nestle, Danone, and Abbvie. M.A., last 3 years received honorarium
from AbbVie; F.M.R. received speaker fees from Schering-Plough,
Nestle´, Mead Johnson, Ferring, MSD, Johnson & Johnson, Centocor,
AbbVie; serves as a board member for: SAC:DEVELOP (Johnson &
Johnson), CAPE (ABBVIE), LEA (ABBVIE) and has been invited to
MSD France, Nestle´ Nutrition Institute, Nestle´ Health Science, Danone,
TAKEDA, CELGENE, BIOGEN, SHIRE, PFIZER, and THERAKOS.
A.A. received research grant from Abbie; S.H. received a travel bursary
from AbbVie; L.d.R., last 3 years received consultation fee, research grant,
or honorarium from ZonMw (National Health Institute), Janssen, Pfizer,
Mundipharma, Shire, and Abbvie; K.K., honoraria for consulting services
(educational services, scientific articles, participation in Advisory Boards,
clinical trials, others) from the companies as follows AbbVie, ENORASIS,
Ferring, JANNSEN, MSD, and Takeda; V.N.L., last 3 years received
consultation fee or honorarium from Abbvie, Otsuka, and Nestle´ Health
Science; S.L., last 2 years received honorarium from Janssen; R.K.R. has
received speaker’s fees, travel support, or has performed consultancy work
with Nestle´ Health Science, AbbVie, Napp, Celltrion, Shire, and Janssen.
E.O. has received honoraria from Abbvie; N.C., research funding for trials,
speaker fees, and travel for conferences from Takeda, Shire, Celgene,
Roche; M.P. lectures and congress fees sponsored by Astellas, Baxter, and
Shire; A.M.G. consultancy, speakers fees, or research support for Abbvie,
Celgene, Ferring, Gilead, Janssen, Pfizer, and Takeda. D.C.W. has received
speaker’s fees, travel support, or has performed consultancy work with
Abbvie, Takeda, and Falk. M.S., C.S., C.B., and C.R. report no conflicts of
interests to declare.
Copyright # 2018 by European Society for Pediatric Gastroenterology,
Hepatology, and Nutrition and North American Society for Pediatric
Gastroenterology, Hepatology, and Nutrition
DOI: 10.1097/MPG.0000000000002036
TABLE 1. Paediatric Ulcerative Colitis Activity Index
Item Points
(1) Abdominal pain
No pain 0
Pain can be ignored 5
Pain cannot be ignored 10
(2) Rectal bleeding
None 0
Small amount only, in <50% of stools 10
Small amount with most stools 20
Large amount (>50% of the stool content) 30
(3) Stool consistency of most stools
Formed 0
Partially formed 5
Completely unformed 10
(4) Number of stools per 24 hours
0–2 0
3–5 5
6–8 10
>8 15
(5) Nocturnal stools (any episode causing wakening)
No 0
Yes 10
(6) Activity level
No limitation of activity 0
Occasional limitation of activity 5
Severe restricted activity 10
Sum of PUCAI (0–85)
For user’s guide and cutoff values for response, remission, mild, moder-
ate, and severe disease activity, refer to the original study (2).
PUCAI ¼ Paediatric Ulcerative Colitis Activity Index.
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Rare cases of mortality have been reported also in children (23),
emphasizing the importance of a structured approach to management
and monitoring during the admission.
Since the publication of the previous European Crohn’s and
Colitis Organization–European Society of Paediatric Gastroenter-
ology, Hepatology and Nutrition (ECCO-ESPGHAN) guidelines on
pediatric ASC in 2011 (1), new data have accumulated regarding
management, diagnosis, and outcomes. We thus aimed to update the
guidelines for managing ASC in children based on a systematic
review of the literature and a robust consensus process from ECCO
and the Paediatric IBD Porto group of ESPGHAN. The methods can
be found in the beginning of Part 1 of these guidelines. Surgical
considerations are also presented in Part 1. (Supplemental Digital
Content include ASC Tables of evidence December 14, 2017,
http://links.lww.com/MPG/B395).
INITIAL MANAGEMENT
Infectious Screening
Recommendations
1. Bacterial causes for ASC should be excluded by a
stool culture including Clostridium difficile toxins A
and B [EL4, adult EL3] (100% agreement).
2. Oral vancomycin should be considered as first-line
therapy for C difficile infection in severe UC [EL4,
adults EL1] (100% agreement).
3. Cytomegalovirus (CMV) colitis should be excluded
in children not responding to 3 days of IVCS [EL4,
adults EL3] (98% agreement).
4. Other infections shouldbeconsidered when relevant,
includingviral and parasitic (eg, cryptosporidium and
amoebiasis), such as in the presence of fever, other
affected household members or non-bloody diar-
rhea; stool testing for Entamoeba histolytica should
be performed in endemic areas or recent travel to
these areas [EL4, adults EL4] (100% agreement).
Practice Points
1. It is important to test for both C difficile toxin A and
B; repeated sampling is required unless a PCR-based
test is available—then 1 stool sample is sufficient
(100% agreement).
2. Oral vancomycin for C difficile should be prescribed
for 10 to 14 days in doses of 10 mg/kg per dose 4
times daily up to an adult dose of 125 to 250 mg
increased if needed to maximum of 500 mg 4 times
daily, although national recommendations vary.
Oral metronidazole may be used in the absence
of oral vancomycin at a dose of 7.5 to 10 mg/kg
per dose 3 times daily (to a maximum of 2 g/24 h)
for 10 to 14 days (100% agreement).
3. CMV infection is best identified by obtaining muco-
sal biopsies via a flexible sigmoidoscopy. Biopsies
should be stained using both hematoxylin eosin and
immunohistochemistry for CMV. Positive PCR in the
absence of inclusion bodies or positive staining is
insufficient for diagnosing CMV since PCR lacks
specificity (100% agreement).
4. For CMVinfection,ganciclovir should be used at adose
of 5mg/kg twice daily for 21 days. Response is
anticipated withina fewdays and management should
be re-considered with an infectious-disease specialist, if
this has not been achieved. Switching to oral valgan-
ciclovir may be considered after several days of suc-
cessful intravenous treatment (100% agreement).
Many gastrointestinal infections have been associated with
pediatric ASC. In 1 retrospective study, 24% (22/92) of flares in
children requiring hospital admission for inflammatory bowel
disease (IBD) were associated with some enteric infection (24).
Stool bacterial culture was positive in 2% of children admitted for
UC exacerbation, as reported in 2 pediatric cohorts (15,25).
C difficile is the most commonly identified organism, rang-
ing in pediatric IBD from 3% to 47% of flares (24–32), compared
with 7.5% per year of follow-up in outpatient pediatric IBD, which
may also include some asymptomatic carriers (33). A C difficile rate
of 25% was reported in a retrospective study of 81 children admitted
with active colonic IBD (compared with 8.9% in non-IBD controls)
(26). An administrative database study among adults and children
showed that the rate of C difficile was >12 times greater in IBD
compared with non-IBD hospitalizations with increasing incidence
over time (29). In hospitalized pediatric and adult IBD patients, C
difficile is associated with increased morbidity including extended
hospital stays, colectomy rate, and even mortality (27,34–43).
Toxigenic culture, the criterion standard for detecting C
difficile, is both time-intensive and expensive (44). Rapid enzyme
immunoassays (EIA) detect a common product of C difficile,
glutamate dehydrogenase, or the toxin products (toxin A and B).
The sensitivity and specificity of both tests vary and recent guidance
advises testing initially for glutamate dehydrogenase EIA and if
positive, confirming the results by EIA for toxins A and B (45–47).
Nucleic acid amplification tests, targeting genes for toxin A and B
by mainly PCR, can be used instead of EIA and due to their high
sensitivity and specificity only 1 stool sample is required (48).
In hospitalized IBD children with C difficile, 75% responded
to metronidazole and the others responded to vancomycin (24).
Similarly, a recent randomized controlled trial (RCT) of metroni-
dazole versus rifaximin for treating C difficile in children with IBD
(not with ASC) showed eradication rate of 71% versus 79%,
respectively (49). A retrospective pediatric case series showed
no difference in response rates between metronidazole (n¼ 15
(41%)) and vancomycin (n¼ 16 (43%)), but results were not
stratified according to disease severity (28). Furthermore, an
increasing number of adult studies show a poorer C difficile
eradication rate with metronidazole (66%–76%) for severe C
difficile infection compared with vancomycin (79%–97%)
(44,50–52). Although a Cochrane systematic review showed no
difference in efficacy between vancomycin and metronidazole, it
was not specific to IBD and most studies excluded severe disease
(53). A diminished colectomy rate (from 46% to 25%) was reported
using vancomycin as primary therapy for C difficile in hospitalized
IBD patients (39). Moreover, hospitalized UC patients with C
difficile had fewer reported readmissions and a shorter length of
hospital stay when treated with oral vancomycin compared with
metronidazole (54). Adult ECCO opportunistic infection guidelines
therefore advise oral vancomycin in severe disease as first line (55).
Fidoxamicin has not been studied in IBD specifically, but in adult C
difficile infection it has been shown to be non-inferior to vancomy-
cin with significantly lower recurrence rates (56–59). Its use is
limited by its high cost compared to vancomycin. There is currently
no evidence to support the use of fecal microbial transplantation
(FMT) in ASC associated with C difficile in children or adults. FMT
is, however, highly effective for eradication of recurrent C difficile
(60) albeit perhaps slightly less in IBD (61) and could be considered
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also in refractory C difficile in UC. A systematic review of FMT
including 22 IBD patients with C difficile showed a response in 20/
22 (91%) (62). A review of 80 immunocompromised adults and
children with C difficile reported a cure rate of 89% with FMT (63).
Systematic reviews in adults have proposed that anti-CMV
treatment may be clinically effective in ASC but there is inconsis-
tency regarding the method of defining CMV infection (64–67).
Recent guidelines report that intestinal CMV disease requires the
presence of multiple inclusion bodies on histology and/or positive
staining on immunohistochemistry rather than merely positive PCR
(68–71). A recent meta-analysis reported benefit of antiviral treat-
ment in steroid-refractory IBD patients (OR¼ 0.20 (95% CI 0.08–
0.49)). The risk of colectomy after receiving anti-viral therapy was
lower in patients in whom CMV was diagnosed based on histology
and/or immunohistochemistry (3 studies; OR¼ 0.06 (95% confi-
dence interval [CI] 0.01–0.34) rather than tissue PCR (64). One
report described a child who underwent colectomy with subsequent
identification of CMV, highlighting the importance of treating true
infections in a timely manner (72). A case report of 6 children with
CMV during an IBD flare suggested that ganciclovir treatment may
be beneficial in some (73). In a recent case-control study from the
Porto group of ESPGHAN including children admitted with ASC
(15 CMV positive and 41 CMV negative), steroid failure was higher
in the 15 CM-positive (93%) than the 41 negative matched controls
(56%, P¼ 0.009) (74). Of the CMV group, 93% were treated with
ganciclovir (5/14 (36%) with 5 mg/kg and 9/14 (64%) with 10 mg/
kg). Colectomy rates were higher in the CMV group on univariate
analysis (33%) versus the CMV negative controls (13%, P¼ 0.049).
Although enteric viruses have been associated with IBD
flares (24,75), limited data exist regarding their role in ASC. In
1 report, enteric viruses were identified in 1% of hospitalized
children with IBD (24). In another small study of 9 IBD children,
norovirus was suggested as a cause for disease exacerbations (75).
The sensitivity of ova and parasites testing in 1 stool specimen
usually slightly exceeds 80% (76,77) and up to 3 samples, as well as
immunofluorescence or EIA for specific parasites, (eg, Giardia
lamblia) increase the sensitivity (77,78). In a retrospective case
control study, cryptosporidium was identified in 4.5% of all pedi-
atric IBD relapses, including hospitalized UC. In that small report,
treatment with nitazoxanide led to a better outcome (79).
Pain Management
Recommendations
1. Non-steroidal anti-inflammatory drugs (NSAIDs)
should be avoided in ASC [EL5, adults EL3] (98%
agreement).
2. Opiates should be used exceptionally with caution
and close monitoring, in doses equivalent to 0.1 mg/
kg morphine, given the remote risk of facilitating
megacolon [EL5, adults EL5] (98% agreement).
Practice Points
1. Bowel perforation or megacolon should be consid-
ered in case of severe or escalating abdominal pain
(100% agreement).
2. Hot packs and paracetamol could be attempted for
pain management (95% agreement).
Despite limited data, withdrawal of opiates has been sug-
gested in adults given the potential of opiates and anticholinergics to
trigger toxic megacolon, possibly due to decreased intestinal peri-
stalsis (80–84). In a pediatric case-control study, 20% of patients
with toxic megacolon received opiates (85), but it is unclear
whether opiates are a marker of disease severity or a true predis-
posing factor for toxic megacolon. There are reports (but not in UC)
that combined prolonged-release oxycodone and naloxone may
manage pain without gastrointestinal complications (86).
In adults with IBD, NSAIDs have been associated with
exacerbation or new onset disease (82,87–92) and thus their use
is discouraged in adult guidelines (80,83). The data are conflicting
regarding selective COX-2 inhibitors, but low doses and short
treatment duration appear to be safe in UC (93–95). Several case
reports describe ketamine use for pain management of IBD (96,97)
including 1 in pediatric ASC suggesting that ketamine may be
effective at reducing opiate and NSAID use (97). Cannabinoids
modulate visceral sensation and pain in animal models (98–100);
however, there is no relevant evidence in ASC and it may be
potentially hazardous given its inhibitory effect on bowel peristal-
sis. There is limited or no evidence for use of clonidine or naloxone
(with opioids) in ASC.
Nutritional Support
Recommendations
1. Regular diet should be continued in most ASC cases.
Enteral (or parenteral in those not tolerating enteral)
nutrition may be used if oral feeding is not tolerated or
in malnutrition [EL4, adults EL1] (98%agreement).
2. Oral or enteral feeding is contraindicated in cases of
megacolon, or when surgery is imminent [EL5,
adults EL5] (100% agreement).
Practice Points
1. Body weight, caloric intake, and hydration status
should be monitored daily, including review by a
dietician as needed (100% agreement).
2. In non-septic patients, standard caloric, protein and
micronutrient intake should be provided according
to age. In malnourished patients or those at risk for
malnutrition, additional calories may be needed,
while monitoring closely for re-feeding syndrome
(100% agreement).
3. There are no data showing a benefit of specific diets
in ASC and thus they should be avoided (98%
agreement).
4. Electrolyte imbalance (especially hypokalaemia and
hypomagnesaemia) can promote colonic dilatation.
Thus, electrolytes should be monitored, at least every
1 to 3 days, according to the degree of the baseline
values and clinical status (98% agreement).
RCTs in adults have shown no benefit of bowel rest in ASC
(101,102). In 1 adult trial in ASC, enteral polymeric nutrition had a
similar remission rate and need for colectomy as compared with
TPN, but a higher increase of serum albumin (17% vs 4.6%,
P¼ 0.019), fewer adverse events (9% vs 35%, P¼ 0.046) and
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fewer postoperative infections (P¼ 0.028) (103). In a retrospective
case series of 15 children with ASC who had bowel rest and
TPN, 5 (33%) required colectomy, which is identical to the
colectomy rate reported otherwise (13). In the prospective
OSCI study of 128 children admitted for ASC (10,74), 58%
were not on solid foods by the third admission day, but in a
multivariate analysis this was not associated with improved out-
come even after controlling for disease activity (personal commu-
nication from DT).
Thromboprophylaxis
Recommendation
1. The use of anticoagulation for preventing venous
thromboembolic event (VTE) is recommended
when 1 or more risk factors are present (according
to age—see practice points) since the relative risk of
VTE is higher during ASC, although the absolute rate
is much lower than in adults [EL5, adults EL4] (98%
agreement).
Practice Points
1. Subcutaneous low molecular weight heparin
(LMWH) should be considered in adolescents with
ASC when 1 or more risk factors are present: smok-
ing, oral contraceptives, complete immobilization,
central venous catheters (including PICC line), obe-
sity, concurrent significant infection (eg, respiratory,
urinary, skin, and intra-abdominal), known pro-
thrombotic disorder, previous VTE, and family his-
tory of VTE. Treatment duration should be
individualized in consultation with the hematolo-
gists (91% agreement).
2. In prepubertal children, further evaluation of the
safety and efficacy of thromboprophylaxis is
required before widespread use. Thus, thrombopro-
phylaxis may be considered in those with at least 2
risk factors (95% agreement).
3. The most common LMWH is subcutaneous enoxa-
parin 1 mg/k/day (100 IU/kg/day) in 1 daily dose.
Monitoring with anti-Xa activity level is not usually
required, except in children with significant renal
impairment (100% agreement).
4. Mobilization,adequatehydration,andprompt removal
of un-needed central venous and arterial catheters,
should be encouraged (100% agreement).
Adult guidelines (104–106) recommend that LMWH should
be commenced in ASC to prevent VT which are much more common
than in quiescent IBD (107–114). Heparin, however, is not effective
for treating the colitis itself, as found in 2 meta-analyses (115,116).
Studies suggest that the risk for VTE complications is
increased also in children with ASC (117–119). Although the
absolute risk of VTE is much lower in children as compared with
adults (9 events per 10,000 patient per years in children vs 24 in
those 40–60 years of age), the odds ratio compared with controls is
higher (OR 5 in children vs2 in the 40–60 years old), given the
low background risk (112). The risk for VTE occurs mostly during
active disease, and more frequently in UC compared to Crohn
disease (120). In a systematic review of pediatric studies, 50% of
IBD children who developed VTE had at least 1 risk factor; 24% of
whom had at least 2 (120). The site of VTE was cerebral in 54%,
limbs in 26%, and abdominal vessels in 26%. Taken together, it
could be concluded that while ASC increases the risk for VTE also
in children, the absolute risk is lower than in adults, especially in the
youngest age groups. Therefore, the presence of one or more risk
factors may identify those who are at particular risk and who would
therefore benefit from thromboprophylaxis (120).
Enoxaparin is the most frequently used drug for prophylaxis
of VTE in children and adolescents (121–123). LMWH at prophy-
lactic doses is effective, well tolerated and safe in children and
adolescents while significant bleeding complications are rare
(124,125). Minor bleeding episodes during prophylactic use of
enoxaparin were reported at 5% to 6% (126,127).
5-ASA Preparations
Recommendation
1. All mesalamine preparations (oral and rectal) should
be discontinued upon admission to exclude mesa-
lamine intolerance, especially when mesalamine has
been commenced during the preceding few weeks;
(re-) introduction should be considered after signifi-
cant improvement in the clinical condition [EL5,
adult EL5] (100% agreement).
The potential minimal effectiveness of oral or rectal mesalamine
preparations is diluted by the severity of the disease in ASC and thus
they are best stopped during the acute phase. There have been case
reports of exacerbation of colitis symptoms in patients with mesala-
mine intolerance (128,129), reported in 2% to 10% of patients (130).
Antibiotics
Recommendation
1. Antibiotics are not routinely recommended in children
with ASC at admission. Empiric antibiotic treatment
may, however, be considered when C difficile or other
bacterial infection is suspected until stool analysis is
available [EL5, adults EL5] (100% agreement).
Two meta-analyses of antibiotic therapy in adult patients with
ASC found 9 RCTs, involving>600 patients, showing a statistically
significant benefit for antibiotics in inducing remission (131,132).
Interestingly, all trials on intravenous antibiotics (133–135) showed
no beneficial effects, whereas most of the trials on oral antibiotics
(136–143) showed some beneficial effects, as observed by Turner
et al (144). Nevertheless, a funnel plot suggested publication bias, and
antibiotic regimens differed substantially. Current adult guidelines
(105,106,145) recommend the use of antibiotics only if infection is
considered, or immediately before surgery.
A small retrospective multicenter study (144) stated that the
use of an oral wide-spectrum antibiotic cocktail (including metroni-
dazole, amoxicillin, doxycycline and—in hospitalized patients—also
vancomycin) in children with moderate-to-severe UC, refractory to
Turner et al JPGN  Volume 67, Number 2, August 2018
296 www.jpgn.org
 Copyright © ESPGHAN and NASPGHAN. All rights reserved.
multiple immunosuppressants, was effective in 47% of patients. This
cocktail has been further explored in in the pilot PRASCO trial, in
which 28 children admitted with ASC were randomized to receiving
the oral antibiotic cocktail as an add-on therapy to IVCS (146). Day 5
PUCAI was significantly lower in the antibioticsþIVCS arm versus
IVCS alone (25 16.7 vs 40.4 20.4, P¼ 0.037), meeting the
primary outcome of that trial. The trial was, however, not powered
to detect differences in need for second-line therapy because there
were only 2 to 3 IVCS failures in each group. Some of the authors of
these guidelines have used the cocktail in treating steroid-refractory
children with ASC as a last resort, at times awaiting colectomy, and a
response has been clearly documented in some. Taken together, a
short course of the oral antibiotic cocktail could be considered in
selected severe refractory cases, while preparing for colectomy.
Antibiotics should be discontinued if no significant response has
been observed in 4 to 7 days. In any case, salvage therapy should not
be delayed for the sake of this attempt.
Corticosteroids
Recommendation
1. Intravenous methylprednisolone 1 mg/k/day (up to
40 mg/day) once daily in the morning is recom-
mended as the initial treatment at admission [EL2,
adults EL1]; a higher dose of 1.5 mg/k/day (up to
60 mg/day) in 1 or 2 divided daily doses should be
reserved to the more severe end of the spectrum and
for children who have failed oral steroids before
admission [EL4, adults EL4] (100% agreement).
Practice Points
1. As there is no firm evidence that the higher dose is
superior to the lower dose, a rapid decline of meth-
ylprednisolone to 1 mg/k/day (40 mg/day) should
be employed once response has been observed
(98% agreement).
2. Methylprednisolone as before has less mineralocor-
ticoid effect and thus is preferred over hydrocorti-
sone (98% agreement).
3. Continuous IVCS infusion has no advantage over
bolus administration (100% agreement).
IVCS leads to clinical improvement in 70% of pediatric
ASC patients and its advent in the landmark trial of Truelove and
Witts was the most important factor in the reduced mortality rate in
ASC during the last century (9–11,21,147–151). Of those not
responding to oral prednisone/prednisolone, approximately two-
third will respond to IVCS. The initial response to corticosteroids is,
however, not influenced by the pharmacokinetics of steroids, and
the reason for the improved effectiveness with intravenous formu-
lation is not entirely understood (11,152,153). Trials in adults with
ASC have shown similar efficacy of adrenocorticotropic hormone
to hydrocortisone (147,154–158).
In an RCT in ambulatory adult patients, remission rate was
higher in patients given oral prednisone 60 or 40 mg daily versus
20 mg daily. Adverse effects were higher among patients given 60 mg
daily (159). In a meta-regression of cohort studies in ASC, mainly in
adults, colectomy rate did not correlate with methylprednisolone dose
at or above 60 mg/day as reported in the individual manuscripts (12).
A prospective multicenter cohort study in children with ASC
(the OSCI study) showed that >70% of patients responded to daily
methylprednisolone dose of 1 to 1.5 mg/kg (up to 40–60 mg) with no
statistical difference in dose between responders and non-responders
(10). Higher doses were also not justified according to a recent
propensity score analysis in a large pediatric cohort of ASC (includ-
ing among others the children from the OSCI study) (160) and, in a
retrospective study among children with ASC, the dose of corticoste-
roids within the standard range was not different between those who
responded and those who failed IVCS (9). Nonetheless, some case
series suggested a benefit to higher and even pulse doses (161–163)
while others did not (164,165). It could be concluded that the majority
of evidence suggests that 40 mg is not less effective than higher doses
in ASC but, given the few anecdotal reports and the severity of ASC, it
is not unreasonable to dose higher in selected patients for several days
until response has been achieved.
Powell-Tuck et al reported comparable efficacy and safety of
once daily oral 40 mg prednisolone to 4 divided doses in ambulatory
UC and this has been traditionally extrapolated to the acute severe
setting (166). This has been supported by another study in adults
with ASC, in which continuous steroid infusion had neither better
efficacy nor safety than bolus administration (149).
Radiography and Toxic Megacolon
Recommendations
1. Abdominal x-ray (AXR) should be performed upon
admission with a low threshold especially in children
with abdominal tenderness or distension, significant
pain and those with systemic toxicity [EL4, adults
EL4] (100% agreement).
2. Children with toxic megacolon, defined in Table 2,
should be evaluated promptly by surgeons and
conservative management should only be consid-
ered in stable clinical conditions and in highly spe-
cialized centers under close monitoring; urgent
colectomy is recommended if no improvement is
apparent within 24 to 72 hours [EL4, adults EL4]
(98% agreement).
Practical Points
1. An abdominal CT-scan or MRI may be indicated in
patients without megacolon on AXR but who have
signs of peritonitis or unexplained deterioration, to
exclude a perforation (98% agreement).
2. Evidence of transverse colon diameter >56mm (or
>40 mm in children younger than 10 years) with signs
of systemic toxicity are diagnostic of toxic megacolon
in children. Features of systemic toxicity for diagnosing
toxicmegacolon inchildren include fever, tachycardia,
dehydration, electrolyte disturbance, altered level of
consciousness, and hypotension; steroids may mask
peritoneal signs (100% agreement).
3. The initial management of toxic megacolon includes,
in addition to IVCS, intravenous fluid resuscitation,
intravenous antibiotics (covering Gram-negative and
anaerobic bacteria, eg, ampicillin, gentamycin, and
metronidazole), bowel rest, and preparation for
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surgery. Insertion of a nasogastric tube, and rectal
decompression tube as well as positional changes
have been used in adults but supportive evidence
is absent in children. Oral vancomycin may be con-
sidered until C difficile status is known (100%
agreement).
4. Cyclosporine, tacrolimus, and anti-TNFs are not
recommended in the routine management of toxic
megacolon, although several successful case reports
have been published (100% agreement).
Toxic megacolon is a rare complication of ASC, occurring in
1% to 2% of pediatric ASC (15) and is associated with a high rate of
mortality if left untreated. Megacolon is easily diagnosed by a simple
AXR film, which may also play a predictive role in pediatric ASC (see
section Monitoring Disease and When to Start Second line Therapy)
(167). Risk factors for toxic megacolon include CMV or C difficile
infection, hypokalaemia, hypomagnesemia, and the use of anticho-
linergics, antidepressants, loperamide, and opioids. Pediatric diag-
nostic criteria for toxic megacolon differ from those of adults, since
altered level of consciousness and hypotension are less frequent in
children (85,168). In adults, long rectal tube insertion combined with
intermittent rolling maneuvers (169) and the knee-elbow position
(170) have been used to promote decompression. Case reports
indicate potential effectiveness of infliximab (171–173), leukocyta-
pheresis (174), tacrolimus (175,176), or hyperbaric oxygen (177) for
treating toxic megacolon, but the evidence is anecdotal. Although
CMV infection is more commonly associated with toxic megacolon,
there is not enough evidence to support empiric treatment with
ganciclovir without confirmation of CMV infection (178).
Ultrasonography by an experienced radiologist directed at
the colonic wall may have a role in providing valuable information
regarding the extent of disease and severity of inflammation.
Civitelli et al’s study of 50 children with UC reported that bowel
wall thickness, increased vascularity, loss of haustra, and loss of
stratification of the bowel wall independently predicted endoscopic
severity (179). Each of these 4 variables was assigned a value of 1
(present) or 0 (absent); a score >2 had a sensitivity of 100% and a
specificity of 93% (area under receiver operator characteristic
[ROC] curve of 0.98) for predicting severe disease at endoscopy.
The ultrasonography score strongly correlated with clinical
(PUCAI, r¼ 0.90) and endoscopic disease activity (Mayo endos-
copy subscore, r¼ 0.94).
Monitoring Disease and When to Start Second-line
Therapy
Recommendations
1. A PUCAI >45 points on the third day of IVCS
treatment should dictate planning for second-line
therapy between days 3 to 5 [EL2, adults EL2]
(100% agreement).
2. Second-line therapy should be initiated on the fifth
day of IVCS treatment in children with a PUCAI >65
points [EL2, adults EL2] (100% agreement).
3. IVCS should be continued for an additional 2 to
5 days in children with a PUCAI of 35 to 65 on day 5;
daily monitoring for confirming gradual response is
recommended before a decision on second-line
therapy is made in most cases within a total of 7
to 10 days of treatment [EL2, adults EL2] (100%
agreement) (Fig. 1).
Practice Points
1. Management of ASC may be initiated in local pedi-
atric centers. Transfer to referral pediatric IBD cen-
ters should take place as needed but certainly by
day 3 of IVCS in patients with a PUCAI >45 (95%
agreement).
2. Recommended planning for second-line therapy
between days 3 and 5 in non-responders (see sec-
tion of second-line therapy) includes sigmoidoscopy
(to detect infectious colitis (most notably CMV),
granulomas, and degree of inflammation), surgical
consult, discussion with a stoma specialist, exclusion
of latent tuberculosis, serology for HBV and HCV,
and/or blood tests required before treatment with
calcineurin inhibitors (creatinine, lipids, and mag-
nesium) (95% agreement).
3. Frequent monitoring of laboratory tests (including
complete blood count, c-reactive protein (CRP), ESR,
albumin, and electrolytes) is advisable as needed but
at least at diagnosis and on days 3 and 5 thereafter.
CRP, albumin, and ESR have some value to predict
TABLE 2. Previously established adult and the currently suggested pediatric criteria for diagnosis of toxic megacolon
Adult criteria (168) Suggested Paediatric criteria (85)
(A) Radiographic evidence of colonic distention
(B) At least 3 of the following:
(1) Fever >388C
(2) Heart rate >120/min
(3) Neutrophilic leukocytosis >10.5 108/L
(4) Anemia
(C) In addition to the above, at least 1 of the following:
(1) Dehydration
(2) Altered level of consciousness
(3) Electrolyte disturbances
(4) Hypotension
(A) Radiographic evidence of transverse colon diameter 56 mm
(or >40 mm in those <10 years)
PLUS
(B) Evidence of systemic toxicity, such as:
(1) Fever >388C
(2) Tachycardia (heart rate >2 SD above mean for age)
(3) Dehydration
(4) Electrolyte disturbance (sodium, potassium, or chloride)
(5) Altered level of consciousness or coma
(6) Hypotension or shock
Reproduced with permission from (1).
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IVCS failure and should be monitored also for that
purpose (100% agreement).
4. Fecal inflammatory markers have no role in the diag-
nosis or management of ASC (95% agreement).
Clinical guidelines for adults recommend that second-line
therapy should be initiated if no response to IVCS is achieved
within 3 to 10 days after initiation as further steroid treatment in
non-responding patients is associated with complications (106).
The most commonly employed adult prediction rule, the Oxford
index, focuses on stool frequency and CRP at day 3 (180). Other
adult rules for predicting steroid refractoriness included also ESR,
hemoglobin, albumin, transverse colon diameter on AXR, and an
Ulcerative Colitis Endoscopy Index of Severity score 7 on
admission (181–185).
PUCAI score at days 3 and 5 is the best validated predictive
and decision-making tool in children with ASC (9,10,186). In a
retrospective study of 99 children with ASC, the PUCAI performed
better than the adult indices to differentiate responders from non-
responders at days 3 and 5 of IVCS treatment (9). These findings
were then validated in the OSCI study of 128 children with ASC
Clinical assessment/Bloods1/Stool2/PUCAI
A child (0-18 years) with acute severe colitis (ASC)
Admission for intravenous 
methylprednisolone 1-1.5mg/kg up to 60mg 
in 1-2 divided doses; 
PUCAI ≥45 PUCAI <45
1. Screen for second line therapy 
2. Check all baseline investigations performed 
3. Involve surgeons if not previously consulted
4. Repeat bloods2 
PUCAI >65 PUCAI 35-65
If infection is suspected or 
proceeding to surgery: 
antibiotics
Withhold 5-ASA, strongly consider 
abdominal X-ray, think about nutrition3 
Continue corticosteroids for 2-5 
additional days and re-enter algorithm 
depending on PUCAI score
If CMV positive consult 
infectious disease 
specialist for therapy 
Continue corticosteroids;  
Consider oral steroids when PUCAI<35 
(see text for discharge 
recommendations)
If toxicity or colonic dilatation4
(see also table 2): NPO, steroids, 
antibiotics and surgical consult 
PUCAI <35
Day 1-2
Day 3
Sigmoidoscopy 
Day 5
Day 6 onwards Continue treatment and monitor progress daily; 
Strongly consider colectomy with any significant deterioration 
Start second line therapy (infliximab, 
tacrolimus or cyclosporine) or 
colectomy (Table 3)
FIGURE 1. Algorithm for management of acute severe pediatric ulcerative colitis (UC). This is a guide to aid the clinician in the management of a
pediatric patient with ASC for timely decision making. It acts as a guide only and does not replace clinical assessment for individual patients. It
should be interpreted in conjunction with the text of the supporting guidelines. (1) Complete blood count, electrolytes, liver enzymes, albumin, C-
reactive protein, erythrocyte sedimentation rate, blood culture (if febrile). (2) Stool culture, viruses and Clostridium difficile toxin. (3) Continue
normal diet if possible. If adequate oral intake is not tolerated, support with enteral tube feeding. If enteral tube feeding is not tolerated or in the
presence of colonic dilatation or when surgery is imminent, then parenteral nutrition may be needed. (4) Dilatation on plain abdominal x-ray is
suggested by colonic width of >56 mm in children older than 10 years of age and >40 mm in younger children. Defined as toxic megacolon if
associated with toxicity (Table 2 in the text). NPO¼nothing per-os. Reproduced with permission from (1).
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(10). A PUCAI > 45 points on day 3 predicted non-response to
IVCS with a sensitivity of 92%, specificity of 50%, negative
predictive value (NPV) of 94% and a positive predictive value
(PPV) of 43%, indicating that complete response is anticipated in
those with PUCAI  45. A PUCAI > 70 points on day 5 was
associated with IVCS failure with a specificity of 100%, PPV of
100%, sensitivity of 35%, and NPV of 79%, indicating that response
is highly unlikely in the presence of PUCAI > 70. Using a cutoff of
>65 points had a specificity of 96%, PPV 82%, sensitivity 49%, and
NPV 82% (10). Likewise, in a retrospective multicenter study of
153 adults, a PUCAI > 45 points on day 3 had an NPV of 88% and
PPV of 54% for salvage therapy (anti-tumor necrosis factor [TNF],
cyclosporine, or colectomy), whereas a PUCAI >65 on day 5 had a
PPV of 85% and NPV of 72% (187). Although a small minority of
children with a day 5 PUCAI > 65 may respond eventually,
delaying second-line therapy has the potential of increasing mor-
bidity in ASC as shown both in children (188) and adults (189).
The PUCAI performed better than 4 fecal markers (calpro-
tectin, lactoferrin, M2-pyruvate kinase [M2-PK] and S100A12), in
predicting IVCS failure in pediatric ASC (186). Ancillary studies
from the OSCI cohort showed that both interleukin-6 (IL-6) (190) and
the microbiome pattern at day 3 (191) have a role in predicting the
need for second-line therapy in children with ASC, but this remains
investigational. Livshits et al (167) reported that findings on AXR
performed on 56 children with ASC during the first 3 days of
admission were different between IVCS responders and non-respond-
ers (mucosal ulcerations: 3% vs 30%,P¼ 0.006; mucosal tags: 9% vs
30%, P¼ 0.073; and megacolon: 0% vs 13%, P¼ 0.064).
Anemia is of particular concern in ASC and blood transfu-
sion should be considered when hemoglobin level is below 8 mg/
dL. Iron replacement without the need for transfusion should be
considered in children whose rectal bleeding has ceased (192).
Intravenous iron infusion has not been widely reported in ASC so
should be used with caution or deferred until after the acute phase
has resolved (193). Generally, there is no need to correct hypoal-
buminemia by albumin infusion unless the reduced oncotic pressure
is associated with clinically significant complications (eg, pulmo-
nary edema, pleural infusions, or dyspnea). Although hypoalbumi-
nemia is associated with a decrease effectiveness of infliximab
treatment, there are no published data that infusing albumin before
infliximab administration improves outcome.
WHEN STEROIDS FAIL
Medical Second-line Therapies
Recommendations
1. Infliximab is recommended as the second-line med-
ical therapy for anti-TNF naive children failing IVCS
[EL3, adults EL1] (100% agreement).
2. Calcineurin inhibitors (tacrolimus and cyclosporine)
can be considered as an alternative second-line med-
ical therapy [EL4, adults EL1] (100% agreement).
3. When introducing second-line therapy, the possibil-
ity of non-response and therefore need for colect-
omy must always be discussed [EL4, adults EL4]
(100% agreement).
Practice Points
1. The role of cyclosporine or tacrolimus as a rescue
therapy is only as a bridge to long-term maintenance
therapy. Hence, among steroid-refractory patients
who have failed prior thiopurine maintenance ther-
apy, infliximab is the preferred second-line medical
therapy, unless bridging to vedolizumab is being
considered (100% agreement).
2. Dosing and target levels for infliximab, cyclosporine,
and tacrolimus are given in Table 3. Other biologics
(eg, other anti-TNF regimens and vedolizumab)
have not been studied in hospitalized steroid-refrac-
tory patients and thus should be generally avoided
as induction treatments in this setting (100%
agreement).
3. Due to rapid clearance of infliximab in ASC, intensi-
fication of induction regimen is often needed to
provide drug exposure equivalent to that attained
with standard dosing outside the ASC setting. Doses
of infliximab up to 10 mg/kg per dose may be
considered and may be given more frequently than
usual (eg, weeks 0, 1, and 4–5). Drug levels
obtained during induction may guide maximization
of efficacy (95% agreement).
4. Response to infliximab or calcineurin inhibitors
should be judged daily by PUCAI and with attention
to serum CRP and albumin. Significant response
(PUCAIdrop of at least 20points) is anticipatedwithin
4 to7 days witheither therapy (100%agreement).
5. To reduce unnecessary immunosuppression, corti-
costeroids (which have been ineffective) should be
weaned following introduction to second-line ther-
apy or decision to proceed to colectomy. The taper
strategy should be individualized based on the prior
steroid exposure and the clinical status (100%
agreement).
6. Among responders to intensified induction, subse-
quent doses of infliximab during maintenance
phase can often be gradually lowered and adjusted
to standard dosing, ideally guided by therapeutic
drug monitoring (100% agreement).
7. Children who develop steroid-refractory ASC are at
particular risk for colectomy within 1 year. There-
fore, the addition of an immunomodulator is recom-
mended in responders to infliximab for at least 6
months. Thiopurine therapy is preferred over meth-
otrexate in UC given its superior effect on treating
the colitis itself. The latter, however, is associated
with reduced risk for lymphoma and thus the risk-
benefit ratio should be individually balanced
(100% agreement).
It is essential that ineffective steroid therapy is not prolonged
unduly and that therapeutic alternatives are considered early,
utilizing a PUCAI-based algorithm on days 3 and 5. Both infliximab
and calcineurin inhibitors are equally effective in inducing clinical
remission in ASC in both children (11) and adults (194,195). Use of
infliximab is, however, currently more common in pediatric prac-
tice, due to greater familiarity with this agent, the ability to continue
as maintenance and the overall better risk-benefit profile (10).
Infliximab
Jarnerot et al first reported that 71% of 45 adults receiving 1
dose of 5 mg/kg infliximab avoided colectomy versus 34% receiv-
ing placebo (183). Observational studies among adult patients have
reported short-term colectomy rates after rescue therapy with
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infliximab ranging from 20% to 75% (196). In the prospective
multicenter OSCI study of ASC in children, 33 of those failing
IVCS received infliximab as rescue therapy, of whom 76% were
able to be discharged without colectomy and the cumulative 1-year
sustained response rate was 55% (18/33) (10,197). Anecdotally, all
8 infliximab non-responders had new-onset disease versus 10 (40%)
of the responders (P¼ 0.03); fecal biomarkers were not useful in
predicting outcome, but higher disease activity, judged clinically, at
admission and days 3 and 5 was associated with reduced response to
infliximab (186,198). Other case series have reported the use of
infliximab in children with ASC, with pooled short-term response
rate of 75% (95% CI 67–83) (n¼ 126, 6 studies), and a pooled 1-
year response of 64% (95% CI 56–72) (11). In another prospective
pediatric study, of 52 subjects who received infliximab (half with
acute severe colitis [ASC]) the steroid-free remission rate at 1 and
2 years was 38% and 21% and the likelihood of avoiding colectomy
by 2 years was 61% (199).
Conventional weight-based regimens of infliximab (5 mg/kg
at weeks 0, 2, 6) used in ambulatory patients may be insufficient
for ASC. Infliximab pharmacokinetics can be influenced by
multiple factors such as body mass index (BMI), serum albumin
level, burden of inflammation, and concomitant use of immuno-
suppressive medications. The influence of these factors on
infliximab clearance has been reviewed specifically in the setting
of ASC (196,200). High concentrations of circulating and tissue
TNF may act as a ‘‘sponge’’ that rapidly absorbs or neutralizes
anti-TNF (201). Excessive fecal losses of infliximab may occur
as a result of protein leakage or blood loss via the inflamed
colon (202).
In support of the need for intensive dosing, Ungar et al found
infliximab trough levels at day 14 to be significantly lower in adult
patients with ASC compared with moderately severe UC patients
(200). Limited data exist concerning optimal target infliximab
levels during induction in any UC patients, and particularly in
the setting of ASC. Among 101 adult patients with UC (but
including only 15 with ASC) treated with standard 5 mg/kg dosing
at weeks 0, 2, and 6, a trough level of 15mg/mL at week 6 best
predicted likelihood of short-term mucosal healing (area under the
ROC of 0.69) (203). The rate of early colectomy was 6.7% in
patients treated prospectively with an ‘‘accelerated’’ induction
regimen, compared with 40% in a group of similar historical
controls treated with the standard induction regimen, but long-term
colectomy rates were similar between the 2 groups (204). In
retrospective analysis of a pediatric cohort of hospitalized patients
with steroid-refractory UC, higher clinical remission rates and a
lower colectomy rate at 1 year were observed with intensified
versus standard dosing (205).
Cyclosporine
In the first RCT on cyclosporine in ASC, Lichtiger et al (206)
reported that 9/11 patients improved on 4 mg/kg/day intravenous
cyclosporine, whilst all 9 receiving placebo failed to improve. In a
TABLE 3. Second-line rescue therapies in pediatric steroid-refractory acute severe ulcerative colitis
Infliximab Cyclosporine Tacrolimus
Tests before
treatment
Excluding tuberculosis; serology for
varicella, hepatitis B, and hepatitis
C (and HIV when appropriate)
Serum creatinine, glucose, electrolytes
(including magnesium), serum
cholesterol
Initial dosing 5–10 mg/kg for dose 1. Emerging
data in ASC indicate that
intensified induction is more
successful than standard 5 mg/kg
given at weeks 0, 2, 6
2 mg/kg/day continuous intravenous
infusion
0.1 mg/kg per dose orally twice daily
Main toxicity Infusion reactions, immune
suppression, and rare opportunistic
infections
Hypertension, hyperglycemia,
hypomagnesemia, immune
suppression, azotemia, seizures (dose
and hypercholesterolemia dependent),
hirsutism, gingival hyperplasia
As per cyclosporine, but less
hirsutism and gingival hyperplasia.
Additionally self-remitting tremor
Ongoing treatment
following
response
Continue regularly scheduled
maintenance infusions (4–8
weeks), ideally guided by
therapeutic drug monitoring
Initiate thiopurines (or other agent to
maintain remission such as
vedolizumab) so that cyclosporine can
be discontinued within several months
As per cyclosporine
Target drug levels
during
induction
Limited data on target levels during
induction
Aim initially for 150–300 ng/mL Aim initially for 10–15 ng/mL
Target levels once
response
achieved
5–10 mg/mL at trough during
maintenance
100–200 ng/mL once remission achieved 5–7 ng/mL once remission achieved;
longer duration treatment using
lower levels of 2–5 have been
reported
Monitoring/
prevention of
toxicity
PJP prophylaxis to be considered with
IMM and steroids
PJP prophylaxis to be strongly considered
with IMM and steroids. Monitor drug
levels, creatinine, glucose, electrolytes
(including magnesium), lipid levels,
blood pressure
PJP prophylaxis to be strongly
considered with IMM and steroids.
Monitor drug levels, creatinine,
glucose, electrolytes (including
magnesium), lipid levels, blood
pressure
ASC¼ acute severe colitis; IMM¼ immunomudolators; PJP¼Pneumocystis jiroveci pneumonia
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further trial among adults with acute severe UC, 73 patients (but not all
failing IVCS) were randomized to either 2 or 4 mg/kg of intravenous
cyclosporine (207). Response rates at day 8 were similar in both groups
(83% and 82%, respectively), with 9% coming to colectomy in the
2 mg/kg group and 13% in the 4 mg/kg group. Pooled results from
controlled and uncontrolled trials in adults suggest that 76% to 85% of
patients respond to intravenous cyclosporine and avoid colectomy in
the short term, with a median time to response of 4 days (208). In a
systematic review of pediatric non-randomized studies, the pooled
short-term success rate with cyclosporine was 81% [95% CI 76–86];
n¼ 94 from 8 studies) (11).
Tacrolimus
Tacrolimus has been studied in 2 double-blind RCTs. In the
first, 60 corticosteroid-refractory UC patients were randomly
assigned to receive oral tacrolimus at high (10–15 ng/mL;
n¼ 19) or low (5–10 ng/mL; n¼ 21) serum trough levels, or
placebo (n¼ 20) (209). Clinical response rates were 68% and
38% in the high and low trough groups, respectively, and 10%
in the placebo. Another RCT treated 62 patients with corticosteroid-
refractory, moderate-to-severe UC with tacrolimus to trough levels
of 10 to 15 ng/mL (210). A clinical response rate of 50% was noted
in the tacrolimus group and 13% in the placebo group at week 2
(P¼ 0.003). A systematic review has combined the data of these 2
trials and other observational studies, and demonstrated that clinical
response at 2 weeks was significantly higher with tacrolimus
compared with placebo (relative risk¼ 4.61, 95% CI 2.09–10.2)
especially in those treated with thiopurines in parallel. Colectomy-
free rates at 1, 3, 6, and 12 months were 0.86, 0.84, 0.78, and 0.69,
respectively (211).
Pediatric studies of tacrolimus as rescue therapy in ASC have
been limited to retrospectively reported single-center case series
and 1 small multi-center prospective study. In the latter, of 14
children with ASC, 69% responded to tacrolimus, but 44% of
responders underwent colectomy by 1 year (212). Short-term
response rates, meaning hospital discharge without colectomy
ranged between 60% and 90% in the retrospective case series, with
at least 40% to 50% requiring surgery by 1 to 2 years (213–216).
Infliximab Versus Calcineurin Inhibitors
Tacrolimus has never been included in a comparative trial
with biologic therapy, but comparable efficacy of infliximab (with
standard dosing) and cyclosporine has been demonstrated in 2
randomized comparative trials in adults (194,195) and in meta-
analysis of retrospective studies (217). The open-label CYSIF trial
showed that treatment failure at day 98 was reported in 60% patients
with cyclosporine versus 54% with infliximab (P¼ 0.49). Colect-
omy rate by day 98 was 18% versus 21%, respectively (P¼ 0.66)
(194). Similarly, the randomized controlled Comparison Of iNflix-
imab and cyclosporine in STeroid Resistant Ulcerative Colitis
(CONSTRUCT) trial found no significant difference regarding
colectomy, mortality rates or the occurrence of serious infections
in 270 patients with steroid-resistant ASC treated with cyclosporine
or infliximab (195).
Close monitoring of cyclosporine and tacrolimus levels is
required, given the narrow margin between therapeutic and toxic
levels. The individual circumstances of each patient should be
considered when deciding between options for salvage therapy.
Calcineurin inhibitors should be avoided in patients with low
cholesterol or magnesium in view of the increased risk for neuro-
logical side effects, in the presence of diabetes, and in those with
azotemia given the potential for renal-toxicity. On the other hand,
infliximab is more costly and if an exit strategy is available
(thiopurines in those previously naı¨ve to thiopurines, or vedolizu-
mab) then calcineurin inhibitors may be equally considered.
Third-line and Sequential Medical Therapy
Recommendation
1. In general, prompt referral for urgent colectomy is
recommended following failure of 1 second-line
medical therapy [EL3, adult EL2] (95% agree-
ment).
Practice Points
1. Despite the above recommendation, in highly spe-
cialized centers and in selected non-fulminant cases,
sequential therapy of calcineurin inhibitors after
infliximab or vice versa may be considered after
weaning off steroids since concomitant steroid ther-
apy is the main contributor for infections. Steroid
substitution therapy may be prescribed at physio-
logical doses to avoid adrenal insufficiency when
needed (95% agreement).
2. Sequential therapy should not be considered unless
an undetectable level of the previous drug has been
documented (93% agreement).
3. If sequential therapy is used, Pneumocystis jiroveci
pneumonia (PJP) prophylaxis should be considered
especially if triple immunosuppressive treatment is
used (98% agreement).
Third-line medical therapy in ASC occurs when sequential
medical therapy is used for salvage of the steroid-refractory
patient—infliximab follows or is followed by a calcineurin inhibitor
(cyclosporine or tacrolimus). This is a separate scenario from
sequential therapy in the chronic active UC patient who is ste-
roid-dependent or refractory. There have been no reports of third-
line therapy in pediatric ASC to date in the literature. A systematic
review of sequential therapy in adult ASC include 10 case series or
cohort studies (314 participants), of which only 1 was prospective
(but no RCT’s) (218). It should be noted that many of the source
studies contained a mixture of chronically active UC and ASC
cases. A short-term response was seen in 62% of patients (95% CI
57–68) and remission in 39% (95% CI 34–44); colectomy rates
were 28% (95% CI 22–35) and 42% (95% CI 36–49) at 3 and 12
months, respectively. Adverse events occurred in 23% (95% CI 18–
28), including serious infection in 7% and mortality in 1%. The
review concluded that the risk of sequential therapy seems lower
than initially reported.
Given the potential for serious adverse events in these adult
series and lack of pediatric studies, extrapolation from adults should
follow the precautionary principal on this matter. It thus would be
prudent to ensure that the levels of the second-line medication have
cleared or nearly cleared before starting the third-line therapy in
pediatric ASC. Furthermore, multiple studies of IBD therapies have
demonstrated that infectious complications are highest with con-
comitant corticosteroid therapy, and thus steroids must be weaned
before third-line therapy is started. Until pediatric data are avail-
able, children with fulminant colitis who cannot safely wait until
weaning must be referred without delay to colectomy.
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SYNTHESIS AND SUMMARY
Discharge Recommendations
Recommendations
1. Children should not be discharged from hospital
unless the disease is at most mild (ie, PUCAI <35
points) but preferably closer to remission (ie, PUCAI
<10 points) [EL3, adult EL3] (98% agreement).
2. Thiopurine maintenance is generally recommended
after ASC responsive to IVCS; exclusive mesalamine
maintenance therapy could be considered if a
response to steroids has been rapid and the patient
was mesalamine naı¨ve before admission [EL4, adult
EL3] (100% agreement).
3. Patients responding to infliximab commenced dur-
ing ASC should continue this drug as a maintenance
treatment post discharge [EL2, adult EL2] (100%
agreement).
Practice Points
1. Before discharge, the following should be ensured:
stable vital signs, adequate oral nutrition, stable
hemoglobin, improving trend in inflammatory mar-
kers and albumin, toleration of oral medication, and
discontinuation of pain-control medications at least
24 hours before discharge (100% agreement).
2. Methylprednisolone should be converted before
discharge to the biologically equivalent dose of
prednisone. One milligram of methylprednisolone
is equivalent to 1.25 mg of prednisone (ie, 40 mg is
equivalent to 50 mg, respectively) (98% agree-
ment).
3. Thiopurines may take 10 to 14 weeks to have full
therapeutic effect and should be introduced at full
dose once the patient is responding to corticoste-
roids (details in Part 1 of these guidelines) (98%
agreement).
4. If cyclosporine or tacrolimus is commenced during
ASC treatment this should be weaned within several
months as a bridge to thiopurine or other mainte-
nance medication, such as vedolizumab, to mini-
mize adverse drug events (98% agreement).
5. PJP prophylaxis with trimethoprim-sulfamethoxazole
should be considered for triple immunosuppression
which includesanti-TNFora calcineurin inhibitorplus
2 other immunosuppressants, mainly steroids. Tri-
methoprim-sulfamethoxazole dosing: 450 mg/m2
twice daily for 3 days each week, (maximum daily
dose 1.92 g) either consecutive or alternate day dos-
ing (note 480mg of trimethoprim-sulfamethoxazole
consists of trimethoprim 80 mg and sulfamethoxa-
zole 400 mg) (100% agreement).
6. Oral iron supplements should be commenced after
discharge in cases of anemia with hemoglobin
10 g/dL and quiescent disease. Intravenous iron
should be considered in severe anemia (ie, <10 g/
dL), active disease or if oral supplements are not
tolerated (98% agreement).
7. Mesalamine may be introduced or re-introduced at
discharge, as appropriate (100% agreement).
8. Children should be reviewed clinically within 2 to
3 weeks of discharge post ASC and then as needed
(98% agreement).
The timing of discharge and tight monitoring of the manage-
ment during the immediate post discharge period are crucial for
avoiding early recurrence. In a post hoc analysis of 37 children with
UC commenced on infliximab (90% moderate-severe activity) a
week 8 PUCAI <10 points best predicted those in steroid-free remis-
sion after 1 year (219). Fifty-three percent of children with a
PUCAI<10 at week 8 compared with 20% otherwise were in remission
(P¼ 0.036). Similarly, in the recent prospective PROTECT study, 148
children with UC were admitted at diagnosis for ASC. Failure to be in
clinical remission (PUCAI< 10) by week 4 was highly associated with
need for additional medical therapy by Week 12 (week 4 remission was
apparent in 80% of those with steroid-free remission at week 12 versus
49% of those with active disease at week 12 and only 6% of those who
required additional therapy;P< 0.0001) (220). It is therefore important
to optimize treatment in those who do not attain complete clinical
remission post discharge.
In the prospective OSCI study in pediatric ASC, the mean
PUCAI decreased from 7212 points on admission to 1813 points
at discharge in those who responded to either steroids or second-line
therapy (P< 0.0001) (10). Of the infliximab responders, 28% (7/25)
were discharged in clinical remission (PUCAI<10 points) and 72%
(18/25) had mild disease at most (PUCAI <35 points) at discharge.
This is in keeping with a study which highlighted a median discharge
PUCAI score of 25 points (interquartile range 15–30) following an
admission for ASC (15). Similarly, in the adult literature there is
evidence that achieving complete clinical remission (3 stools/day
with no visible blood) during the index hospital admission improves
long-term outcome and delays the need for colectomy (221).
Post pediatric ASC discharge, 49% of initial IVCS respond-
ers lost clinical response despite maintenance mesalamine or
thiopurine therapy during the subsequent 1 year and 14% became
steroid dependent (10). In order to limit steroid exposure to the
minimum necessary, expert consensus steroid tapering algorithm
has been proposed (see table in Part 1 of these recommendations).
Azathioprine has been shown to be superior to mesalamine in
maintaining remission post IVCS in 1 small pediatric study (222).
Two adult RCTs also showed superiority of thiopurines over
mesalamine (223,224). A combination of azathioprine with mesa-
lamine leads to higher 6-thioguanine (6-TGN) levels and improves
the likelihood of avoiding rescue therapy at 2 years, as found in a
prospective multicenter study (225,226). Given the severity of
ASC, the higher likelihood of colectomy in the subsequent year
(7,10), and the excellent safety profile of mesalamine, combination
therapy of mesalamine with thiopurines should be favored. If
exclusive mesalamine treatment is to be used, there should be a
low threshold for treatment optimization and escalation.
Calcineurin inhibitors should be used only as a bridge to
thiopurines or other maintenance treatment such as vedolizumab
after several months to avoid toxicity (214,227). Success rate is
higher in children who are treated with cyclosporine combined with
immunomodulatory therapy before discharge with a pooled long-
term colectomy-free rate of 71% (55%–83%) (11,228,229). Being
thiopurine-naı¨ve is associated with lower colectomy risk in adult
ASC (230–234). Maintenance with vedolizumab post induction
with calcineurin inhibitors could be considered in those who failed
thiopurines before the admission.
IBD patients are at an increased relative risk of PJP (HR,
2.96; 95% CI 1.75–4.29) but low absolute risk (235). PJP has been
described in IBD patients on corticosteroids, calcineurin inhibitors,
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thiopurines, and anti-TNF agents (236–241), while a recent admin-
istrative study showed low risk even on triple therapy (albeit the
vast majority were not during an ASC episode) (242). There is only
1 pediatric IBD case report of PJP (associated with infliximab
monotherapy) (243). Corticosteroids are a major contributor to PJP
in the non-HIV population and the use of multiple immunosup-
pressive agents increases the risk further (244–247). To date, 162
cases of PJP are reported in the IBD and rheumatology literature
associated with anti-TNF therapy with a 20% to 27% mortality rate
(235,240,241,243,248–257). A meta-analysis of prophylactic treat-
ment with co-trimoxazole in patients with hematological cancers
and transplant recipients reported a 91% reduction in PJP incidence
(258). As there are no robust studies in children, benefits of
treatment must be balanced against medication side effects. The
ECCO opportunistic infection guidelines recommend PJP prophy-
laxis in IBD patients on triple immunosuppression with one of these
being either a calcineurin inhibitor or anti-TNF therapy (55).
CONCLUSIONS
Based on systematic review of the literature and a consensus
process, we yielded 24 recommendations and 43 practice points.
We have attempted to provide some practical guidance even when
data were insufficient. In these cases, we emphasized that the
guidance is based on common knowledge and experts’ opinion.
Recognizing the unique considerations in children, some of the
recommendations are different than those published for adults.
We have summarized the recommendations in a treatment
algorithm; this must be used in conjunction with the supporting text
(Fig. 1). These clinical management guidelines were developed to assist
practitioners at all levels of health care, while recognizing that each
patient is unique. The recommendations may, thus, be subject to local
practice patterns, but serve as a general framework for the management
of ASC in children. The development of the guidelines should now be
followed by dissemination of the information to clinical practice.
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